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Saudi Journal of Ophthalmology (2012) 26, 323–326Original ArticleLong term comparison between single stage Baerveldt and Ahmed
glaucoma implants in pediatric glaucomaNehal M.S. El Gendy, MBBch, MD a,b; Jonathan C. Song, MD a,c,⇑AbstractPurpose: To compare the long term intraocular pressure control in pediatric glaucoma patients who underwent single stage
Baerveldt glaucoma valve and Ahmed glaucoma valve S2 implantation.
Study design: A retrospective study was conducted to analyze the data of patients with single stage Baerveldt glaucoma valve and
Ahmed valve implantation at Children Hospital Los Angeles.
Methods: Medical records of patients were reviewed retrospectively and divided into two groups. All cases received single stage
valve implantation in which the tube was inserted primarily into the anterior chamber. In cases with Baerveldt implants, the silicone
tube was ligated near its plate location with a single absorbable suture. Group 1 included patients with Baerveldt glaucoma
implant model BG 101–350, while group 2 included patients with Ahmed valve implant model S-2. Patients’ data collected ranged
over the period from 2001 to 2008. The minimum follow up period was 6 month; maximum follow up period was 8 years. All
patients were below 18 years of age. Success was considered if last postoperative IOP was between 8 and 24 mm Hg (with or with-
out medications), no additional glaucoma surgery after valve implantation, and absence of visually significant complications.
Results: Group 1 included 20 cases and group 2 included 11 cases. Long term success rate based on criterion defined was 80% for
group 1 (Baerveldt) with average IOP postoperatively on last follow-up of 19.6 mm Hg. In group 2 (Ahmed), average postoperative
pressure was 24 mm Hg with 6 out of 11 considered successful based on criterion giving 54.5% success rate.
Conclusion: In the long term, single stage Baerveldt implantation appears to control pressure well in pediatric glaucoma.
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Pediatric glaucoma is a potentially blinding disease. Treat-
ment options remain mainly surgical. Mild cases are treated
primarily by goniotomy and or trabeculotomy, if angle cannot
be visualized. Success rate up to 77% for congenital/infantile
glaucoma have been reported. In cases were both goniotomy
and trabeculotomy fail treatment options become limitedPeer review under responsibility
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tive procedure, and valve implantation.1,2
Trabeculectomy without antifibrotic agent had been asso-
ciated with a variable rate of success ranging from 37% to
85%.3–10 This widely variable rate of success has limited the
predictability of such procedure in pediatric glaucoma. The
addition of antifibrotic agents such as mitomycin C to trabec-
ulectomy procedure has been associated with short termProduction and hosting by Elsevier
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324 N.M.S. El Gendy, J.C. Songsuccess rate ranging from 67% to 100%.11,12 However, long
term serious complications such as bleb leakage and infec-
tions have been a worrisome factor. Cyclodestructive proce-
dure has been limited by the higher incidence of phthisis
bulbi.13,14 Aqueous drainage devices were first suggested
by Molteno in 1973, with a success rate of 67%.15 More re-
cently, popular used glaucoma valves include the Ahmed
valve and Baerveldt glaucoma valve.
In our study we evaluated the long term outcome as re-
gards to intraocular pressure control (IOP), need of further
surgeries and success rate of patients less than 18 years with
single stage Baerveldt valve implantations as compared to
Ahmed glaucoma valve implantation.
Methods
The study was registered with the institutional review
board (IRB) and was approved by ethics committee of the
institution.Preoperative data collected
Data obtained from chart review included age at surgery,
glaucoma etiology, associated ocular or systemic diseases,
highest IOP recorded preoperative (despite of medications),
number of anti-glaucoma medications used, and previous
operations.Operative details
All cases were done under general anesthesia; intraocular
pressure (IOP), cup to disc ratio (C/D), and slit lamp examina-
tion were done in all patients after induction of anesthesia.
All patients were prepped and draped in usual sterile man-
ner. Lid speculum was applied. 6-0 vicryl corneal retraction
suture is placed at 12 o’clock to allow for exposure of the
superior temporal quadrant. Conjunctival incision 7–8 mm
from the limbus was made, and then released both medially
and temporally; tenon layer was elevated and cut down to
bare sclera. Anterior dissection into clear corneal, limbal junc-
tion was made. Posterior dissection is made to reveal the
superior temporal quadrant and bare sclera. In 20 cases,
Baerveldt implant model BG 101–350 was implanted. The
tube was flushed first with BSS to ensure its patency. The
wings of the implant were inserted one under the superior
rectus the other under the lateral rectus. The implant was
fixed using two 8-0 nylon sutures 9 mm from the limbus.
The sutures were rotated to bury the knot. 6-0 vicryl suture
was placed to tie of the tube to prevent flow near its site of
insertion to the plate. The tube was then trimmed to size
and a 23 gauge needle was used to enter the anterior
chamber, tube was inserted into anterior chamber. Tube
fenestration was made and a sclera patch graft was then
applied to cover the anterior portion of the tube. Tenon
and conjunctiva were then closed using 8-0 vicryl BV sutures
in continuous manner.
Eleven cases were implanted with Ahmed valve model S-2,
the technique followed similar steps to that of Baerveldt.
Rectus muscle did not need to be isolated. Ligation of the
tube and fenestration was not needed given the valved
nature of this implant. In all cases subconjunctival antibiotic
and steroid were given and a light patch was applied.Postoperative data collected
Included 6 month, 1 year and last visit postoperative IOP,
total duration of follow up, number of medications used, reo-
perations. Success was defined as IOP between 8 and 24, no
further glaucoma surgeries indicated, and absence of vision
threatening complications.
Data analysis
Results are given as mean + SD with range indicated.
Statistical comparisons were performed using paired sample
t tests. P value less than 0.05 was considered statistically
significant.Results
Patients were divided into two groups, group 1 (Baerveldt
implant BG 101 model 350) and group 2 (Ahmed valve im-
plant model S-2).
Group 1 included 20 cases, 12 cases were congenital glau-
coma, 8 cases were secondary glaucoma (4 aphakic glau-
coma, 1 neovascular glaucoma, 1 congenital hereditary
endothelia dystrophy (CHED), 1 aniridia, and 1 steroid
induced glaucoma. Nine cases were associated with other
ocular diseases (aniridia, sturge weber, pars planitis, ocular
rubella, CHED, ROP (retinopathy of prematurity), PHPV (per-
sistent hypertrophic primary vitreous), and microphthalmia)
while two cases were associated with systemic diseases
(mental retardation and intra-uterine rubella infection). Age
ranged from 6 month to 18 years of age (average 5.4 years).
Average preoperative highest recorded IOP was 33.8 ±
5.7 mm Hg using tonopen. Average numbers of medications
were 2.3 ± 1.1 used preoperatively. Average preoperative
C/D ratio was 0.8 ± 0.2. Average age at surgery was 5.4 ±
5.1 years. Average IOP 6 month postoperative was 17.4 ±
8.2 mm Hg; 1 year postoperative was 19 ± 6.9 mm Hg. Total
follow up period ranged from 1 to 6 years in group one with
average of 3.8 ± 2.4 years. Average IOP in last postoperative
visit was 18 ± 5.7 mm Hg on average number of anti-
glaucoma medications of 1.5 ± 1.2, C/D ratio of 0.6 ± 0.2.
Average age at last follow up was 9.5 years (range
2–19 years). Four cases out of twenty were considered unsuc-
cessful according to criteria mentioned above (80% success
rate for group 1).
Demographic data of group 1 are summarized in Table 1.
Group 2 included 11 cases, 5 cases were congenital
glaucoma, 6 cases were secondary glaucoma (1 aphakic
glaucoma, 2 anterior segment dysgenesis, 2 uveitis, 1 with
iridocorneal endothelial syndrome). Six cases were associ-
ated with other ocular diseases, while no cases were associ-
ated with systemic diseases. Age ranged from 7 month to
17 years of age (average 6.7 years). See Table 2. Average
preoperative highest recorded IOP was 39.8 ± 6.2 mm Hg
using tonopen. Average numbers of medications were
2.7 ± 1.9 medications used preoperatively. Average preop-
erative C/D ratio was 0.75 ± 0.1. Average IOP 6 month post-
operative was 19.6 ± 6.1 mm Hg; 1 year postoperative was
24 ± 5.4 mm Hg. Total follow up period ranged from
6 month to 7.5 years with average of 2.7 ± 2.5 years. Aver-
age IOP in last postoperative visit was 24 ± 8.7 mm Hg on
an average number of anti-glaucoma medications of
Table 1. Demographic data of group 1.
Study number Date of birth Sex Diagnosis Associated ocular disease Associated systemic disease Age at surgery
1 12/27/1992 m lt aniridia Yes No 10
2 10/28/2000 m lt congenital Yes No 2
3 4/19/1984 f lt congenital No No 18
4 10/27/1992 m rt NVG Yes No 10
5 11/30/1998 f lt aphakic glaucoma No No 3
6 8/10/1990 m lt CHED Yes Yes 11
7 9/22/2005 m rt congenital No No 0.5
8 1/20/2004 f rt aphakic glaucoma No No 2
9 4/12/2004 f rt aphakic glaucoma Yes No 1.3
10 3/20/1997 f lt congenital Yes No 7
11 3/4/1992 f lt aphakic glaucoma Yes Yes 12
12 6/5/1995 m lt congenital No No 9
13 4/21/2003 f rt congenital No No 0.7
14 4/21/2003 f lt congenital No No 0.75
15 1/20/2000 m lt congenital No No 3
16 3/28/2001 m lt congenital glaucoma No No 7
17 3/28/2001 m rt congenital No No 7
18 9/10/2007 m rt steroid induced Yes Yes 1.3
19 10/6/2007 m lt congenital No No 0.75
20 1/25/2003 m lt congenital No No 1.5
f = female, m = male, nr = no record, rt = right, lt = left, NVG = neovascular glaucoma, CHED = congenital hereditary endothelial dystrophy.
Table 2. Demographic data of group 2.
Study number Date of birth Sex Diagnosis Associated ocular diseases Associated systemic disease Age at surgery
1 10/21/1999 f lt congenital glaucoma No No nr
2 12/3/1996 f lt congenital glaucoma Yes No 4
3 7/23/1996 m rt secondary glaucoma Yes No 4
4 8/19/1997 m rt secondary glaucoma Yes No 8
5 7/25/1998 m lt congenital glaucoma No No 2
6 6/6/1997 m lt congenital glaucoma No No 2.5
7 10/15/1999 f rt secondary glaucoma Yes No 6
8 10/15/1999 f lt secondary Yes No 9
9 10/18/1986 f lt secondary Yes No 14
10 4/15/1982 f rt secondary glaucoma Yes No 17
11 3/25/2002 f lt congenital glaucoma No No 0.56
f = female, m = male, nr = no record, rt = right, lt = left.
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Average age at last follow up was 9.7 ± 6.2 years (range
2.5–21.5 years. Five cases out of 11 were considered unsuc-
cessful according to criteria mentioned above (54.5% suc-
cess rate for group 2).
Number of congenital glaucoma was comparable in the
two groups, 12 cases out of 20 cases group one (60%), 5
cases out of 11 cases (45.5%) group 2. The mean age in both
groups was 5.3 years Group 1, 6 years group 2; the difference
was statistically not significant P = 0.7. The maximum preop-
erative IOP measurement difference between the two groups
was statistically significant P = 0.02.
Difference between postoperative follow up period was
statistically not significant P = 0.3 with longer average post-
operative follow up period for Group 1.
Postoperative last visit IOP was higher for Group 2 (24 mm
Hg) compared to Group 1 (17.4) and the difference between
the two groups was statistically significant P = 0.03. Average
number of medication needed postoperatively was more for
Group 2, the difference was statistically not significant
P = 0.14.
Discussion
Although glaucoma drainage implants have been used
since 197016, success rate has been very controversial withminimal data about long term success rate and preferred
type of implants for pediatric glaucoma. We compared the
results of the two more commonly used pediatric glaucoma
implants, Baerveldt and Ahmed implants, done by the same
surgeon over a period of time.
Previous studies have demonstrated that greater implant
surface area is associated with a greater lowering of IOP;
however, this theory remains controversial.17,18 Baerveldt
implant model 350 has a wider implant surface area than
Ahmed valve. A study by De Moura et al., in 2005 19 showed
no significant difference between the success rate of
Baerveldt implants 350 mm2 and 500 mm2. In our study, only
Baerveldt implant 350 mm2 was used.
Success rate of Ahmed valve implants in children has been
varied. In a study by Englert et al.20 in 1999, the success rate
of Ahmed used in patients younger than age 18 years was
85.2% at last follow-up. In our study, Ahmed valve success
rate was 54.5%, however, in Englert’s study follow up was
mainly for 3 month, in our study follow up period ranged
from 6 months to 7.5 years (average 2.7 years). Morad et
al., using the Ahmed implant in 44 patients, reported
decreasing success rate with time; 93% at 1 year, 86% at
2 years, 71% at 3 years, and 45% at 4 years. 21
Baerveldt implant has been used in pediatric glaucoma, In
De Moura’s study, success rate was 77.1%19, compared to
our results (80%). It should be noted that in De Moura’s
326 N.M.S. El Gendy, J.C. Songstudy, some cases received Baerveldt implant as the primary
line of treatment. In the study when comparing single-stage
and two-stage implantation, there was no difference in the
probability of success (success, single stage in 20 [71%] of
28 eyes; success, two-stage in 17 [85%] of 20 eyes; P = .32),
nor did the location of the tube result in different probabili-
ties of success (anterior chamber successful in 24 [71%] of
34 eyes; posterior chamber successful in 11 [79%] of 14 eyes;
P = 1.00). In our study, all cases underwent single stage sur-
gery, three cases had pars plana tube insertion; the three
cases met the criteria of success. No specific complications
were associated with single stage Baerveldt implantation
with absorbable suture ligation.
The success rate of glaucoma implant surgery in our study
was comparable with previous studies. Baerveldt implant suc-
cess rate was higher than Ahmed valve success rate in our
study, with lower postoperative IOP, and lower number of
postoperative medications needed to maintain a suitable
IOP. The number size and retrospective nature of this study
have their limitations. The two sample groups were not as
homogeneous and may be the reason why the final IOP in
group 2 was higher. We also defined success rate as pressure
of 24 or lower in our study which is different from previous
studies. This was done given that many of our last pressure
in these children were obtained with the child awake. Due
to the child’s degree of cooperativeness higher pressures
may be seen in these children. Pressure of 24 or below as
what was used by the treating physician in which the child
was considered stable at the time, with no medications
added and no additional surgery needed. In addition, with
new model of Ahmed implant FP7, pressure control and heal-
ing characteristics in the long term may be different as com-
pared to Ahmed S2 model. Future studies of interest include
a prospective randomized study of different implants that are
available in treatment of pediatric glaucoma. Due to these
reasons, we cannot conclude whether or not one implant is
better than the other; however, we can conclude that a single
stage Baerveldt implant can be a successful, safe method for
treatment of intractable glaucoma in children.
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